News > AstraZeneca admits manufacturing error, Covaxin phase-3 trials to start in Gujarat

AstraZeneca admits manufacturing error, Covaxin phase-3 trials to start in Gujarat

AstraZeneca and Oxford University have acknowledged a manufacturing error which has raised questions about preliminary results of their experimental Covid-19 vaccine.

In a surprise, the group of volunteers that got a lower dose seemed to be much better protected than the volunteers who got two full doses. In the low-dose group, AstraZeneca said, the vaccine appeared to be 90 per cent effective. In the group that got two full doses, the vaccine appeared to be 62 per cent effective.